HomeSmall Caps
Share

Sellas Life Sciences skyrockets 156% after cancer vaccine extends survival in trial

Maria Dranishnikova

Maria Dranishnikova

Oninvest reporter
The companys vaccine to treat an aggressive form of blood cancer reduced the risk of death by 41% compared with the best available treatment for patients / Photo: Nan Tun Nay / Shutterstock

The company's vaccine to treat an aggressive form of blood cancer reduced the risk of death by 41% compared with the best available treatment for patients / Photo: Nan Tun Nay / Shutterstock

Shares of Sellas Life Sciences, a small biotech start-up, surged 156% on Tuesday after the company reported that its cancer vaccine reduced patients’ risk of death and helped them live longer than those receiving the best available treatment. Wall Street’s average target price implies the stock could roughly double from here.

Details

Sellas Life Sciences shares jumped 156% on the Nasdaq on Tuesday, their biggest one-day gain since 2020, Bloomberg reports. The shares closed at $19.15 apiece, their highest level since 2019. The rally put Sellas’s market capitalization at $3.9 billion at the close.

The rally began after Sellas released topline results from the phase III trial of its cancer vaccine, galinpepimut-S (GPS), the final stage of clinical testing. The company tested the vaccine in patients with acute myeloid leukemia (AML), an aggressive form of blood cancer, who had gone into remission after a second or later course of treatment and could not undergo a stem cell transplant.

The trial showed that GPS reduced the risk of death by 41% in patients with AML. Median overall survival, the point at which half the patients were still alive, was 24 months for those who received the vaccine versus 14.7 months for those who received the best available treatment.

Sellas plans to discuss an accelerated filing strategy with the U.S. Food and Drug Administration as it prepares to submit a vaccine approval application in the first half of 2027.

Moderna jumped following its third-quarter earnings report / Photo: Unsplash.com / Ian Hutchinson

Moderna surges 700% on cancer vaccine hopes. Covid still drives 3Q revenue.

After Tuesday’s close, the biotech announced a proposed $150 million stock offering and said it planned to give underwriters an option to buy up to $22.5 million in additional shares. The announcement sent the stock lower in after-hours trading on Tuesday. It was down 6% in premarket trading on Wednesday as of this writing.

What analysts say

“This represents blockbuster data for a difficult indication and, if approved, could lead to GPS becoming the standard of care,” Alliance Global Partners analyst James Molloy wrote in a note cited by Bloomberg. Bloomberg writes that Sellas’s results add to the growing evidence of the potential for cancer vaccines, following promising data on a melanoma vaccine from drugmakers Moderna and Merck & Co.

Some investors had bet against GPS, Bloomberg notes. Short interest had reached 29% of Sellas’s free float, according to data from S3 Partners, reflecting bearish bets against the biotech.

Both Wall Street analysts who cover Sellas have a “buy” rating on the stock. Their average target price of $37.50 per share implies around 96% upside from the last close.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News